

Multiple **MY**eloma: an epidemiolo**GO**logical study using SNIIRAM **D**atabase

Treatment pathways for patients with Multiple Myeloma: a real-life study based on the French national claim database from 2014 to 2019

Aurore Perrot¹, Vincent Augusto², Marie Pierres³, Matthieu Javelot³, Caroline Guilmet³,
Martin Prodel⁴, Ludovic Lamarsalle⁴, Marie Laurent⁴, Isabelle Borget⁵, Cyrille Touzeau⁶

1. Institut Universitaire du Cancer Toulouse, 2. Center for Biomedical and Healthcare Engineering Mines, 3. JANSSEN Cilag France,
4. HEVA, 5. Institut Gustave Roussy, 6. Centre Hospitalier Universitaire de Nantes

Disclosure of interest

Aurore Perrot


Disclosures of interest:

Janssen, Amgen, BMS/Celgene, GSK, Takeda and Sanofi

The MYLORD study was financed by JANSSEN-Cilag France

Introduction

Context and objective



Cohort of patients treated for a Multiple Myeloma (MM) in France

- Using French NHI database (SNDS)
- **40 747 patients** from 2014 to 2019, and among them 36 241 for whom treatment history has been identified using an AI algorithm (ATLAS)
- The **most extensive** and **exhaustive** cohort of MM in France
- Methodology and 1st study results presented at **EHA congress**



Objective : describe treatment pathways and attrition rates across lines of treatments in MM patients

Methods

Patients identification and statistics



Patients' identification

- Using MYLORD cohort
- **Inclusion of patients who initiated a L1 in 2014 and in 2015** to get enough follow-up
- Follow-up until December 31st, 2019 (or death)




Statistical analyses

- Attrition rate across lines of treatment
- Treatment sequences
- Survival using Kaplan Meier method

Results


Cohort of patients



Results


Patients characteristics

N=7 118




Results

Survival curves



Results


Treatment lines flow for patients with a line 1 with transplant



All-cause of deaths are considered in this study

Results

Treatment lines flow for patients with a line 1 without transplant




All-cause of deaths are considered in this study

Results

Treatment sequences for patients with a line 1 with transplant

- BP, BVd
- MP, MPT
- VMP
- V
- Pd
- D mono
- VTd
- Rd
- VRd
- Triplets
- Others




Main course:

- L1: VTd
- L2: Rd
- L3: Pd
- L4: D mono

Results

TTNT for each line
for patients with a
line 1 with transplant




- Line 1
- Line 2
- Line 3

Results

*Treatment sequences
for patients with a line 1 without
transplant*


- BP, BVd
- MP, MPT
- VMP
- V
- Pd
- D mono
- VTd
- Rd
- VRd
- Triplets
- Others



- Main course:
- L1: VMP
 - L2: Rd
 - L3: Pd
 - L4: D mono

Results

TTNT for each line
for patients with a
line 1 without transplant



- Line 1
- Line 2
- Line 3

Conclusion

- **High attrition rate**, especially in older patients

57% in another cohort

Fonseca et al, BMC Cancer 2020

Many patients would not have the opportunity to be treated with several lines

→ **Initiate new treatments as early as possible**

- Fast evolving therapeutic landscape

→ **Important role of RWE studies to describe changes and could be used to compare treatment sequences in terms of effectiveness but also in a pharmacoeconomic perspective**

- **Ongoing cohort**

Thank you for your attention